Provides relative to certain pregnancy screenings. (gov sig) (EN INCREASE GF EX See Note)
Summary
SB 174 revises Louisiana’s pregnancy screening requirements and adds a new prenatal substance use disorder screening provision. The bill requires healthcare providers to offer or provide HIV and syphilis blood tests at the first prenatal visit in the first trimester, again at the first prenatal visit in the third trimester, and at labor and delivery unless the pregnant woman declines testing. It also requires testing for chlamydia and gonorrhea at the first prenatal visit, with additional third-trimester testing if the patient tests positive or the provider deems it necessary.
The bill further creates a new requirement that licensed prenatal care providers screen pregnant women for substance use disorder during the first trimester or at the first visit after pregnancy is confirmed, using a validated verbal screening tool aligned with American College of Obstetricians and Gynecologists standards. If the screening indicates risk, the provider must refer the patient for appropriate treatment. The Louisiana Department of Health must post approved screening tools on its website.
Impact
SB 174 amends R.S. 40:1121.21 and enacts R.S. 40:1123.5, expanding mandatory prenatal screening obligations for physicians and other licensed healthcare providers. It also defines the new testing and screening duties for prenatal care, labor and delivery, and related providers, and it requires health insurance issuers and managed care organizations to treat the covered testing as medically necessary without prior authorization or utilization management barriers. The bill therefore affects both clinical practice and insurance coverage rules for prenatal infectious disease testing and substance use disorder screening.
Sentiment
The bill appears to have broad bipartisan support and little visible opposition. It passed the Senate 37-0, the House 97-0, and the Senate concurrence vote 39-0, indicating unanimous approval in both chambers. The lack of committee transcript material suggests no recorded public controversy in the available record, and the voting history reflects a generally favorable view of the bill’s public health goals.
Contention
No specific points of contention are documented in the available committee materials, but the bill’s policy choices could raise practical questions for providers and insurers. Potential areas of concern include the expanded testing obligations at multiple prenatal stages, the requirement to use validated verbal screening tools for substance use disorder, and the mandate that insurers cover the services without prior authorization. Any debate would likely center on implementation burdens, patient consent and privacy, and the scope of provider responsibilities rather than the bill’s overall public health purpose.